Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $49.70
    -0.95 (-1.88%)

    Market Cap: $4.86B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Travere Therapeutics Inc (TVTX) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Travere Therapeutics reported EPS of -$0.55, below the -$0.25 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    55%(21/38)
    Avg Surprise
    +33.83%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.48
    Range$0.09 - $0.99
    16 analysts
    Revenue Consensus
    $243.08M
    Range$206.78M - $279.30M
    16 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$1.05
    Range$0.80 - $1.27
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.96+9.6%
    60d ago$1.01+4.0%
    30d ago$1.01+4.0%
    7d ago$1.05-0.4%
    Current$1.05
    Revenue Consensus
    $254.72M
    Range$231.81M - $282.20M
    8 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 29.7% above the $0.37 reported for the quarter ended Dec 31, 2025.

    TVTX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    TVTX Earnings Call

    The latest TVTX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, TVTX beat 21, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $224.56M, up 36.2% from $164.86M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.55-$0.25-$0.57 - $0.71-120.00%Miss-193.2%82 up, 0 downNov 2, 2026$224.56M
    Jun 30, 2026-$0.37-$0.14N/A-164.29%Miss-384.6%82 up, 0 downAug 4, 2026$169.58M
    Mar 31, 2026$0.05-$0.06-$0.25 - $0.18+183.33%BeatN/A60 up, 1 downMay 4, 2026$127.20M
    Dec 31, 2025$0.37-$0.04N/AN/AN/AN/A73 up, 0 downFeb 19, 2026$129.69M
    Sep 30, 2025$0.59-$0.08-$0.25 - $0.01+837.50%BeatN/A84 up, 2 downOct 30, 2025$164.86M
    Jun 30, 2025$0.13$0.04-$0.15 - $0.14+225.00%BeatN/A81 up, 1 downAug 6, 2025$114.45M
    Mar 31, 2025-$0.19-$0.39-$0.51 - -$0.27+51.28%BeatN/A70 up, 4 downMay 1, 2025$81.73M
    Dec 31, 2024-$0.47-$0.38-$0.52 - -$0.28-24.14%MissN/A73 up, 0 downFeb 20, 2025$74.79M
    Sep 30, 2024-$0.46-$0.54-$0.97 - -$0.50+14.81%Beat-120.3%105 up, 1 downOct 31, 2024$62.90M
    Jun 30, 2024-$0.65-$0.72-$1.06 - -$0.64+9.72%BeatN/A100 up, 0 downAug 1, 2024$54.12M
    Mar 31, 2024-$1.51-$0.79-$1.27 - -$0.78-91.14%MissN/A110 up, 1 downMay 6, 2024$41.37M
    Dec 31, 2023-$0.94-$0.92-$1.57 - -$0.85-2.17%MissN/A123 up, 0 downFeb 15, 2024$45.06M
    Sep 30, 2023$2.27$0.04-$1.35 - $1.67N/AN/AN/A112 up, 0 downNov 7, 2023$37.09M
    Jun 30, 2023-$0.77-$0.93-$1.30 - -$0.93+17.20%BeatN/A111 up, 1 downAug 3, 2023$32.20M
    Mar 31, 2023-$0.82-$1.03-$1.49 - -$0.77+20.39%BeatN/A92 up, 0 downMay 4, 2023$56.99M
    Dec 31, 2022-$1.03-$1.07-$1.35 - -$0.88+3.74%BeatN/A91 up, 2 downFeb 23, 2023$55.87M
    Sep 30, 2022-$0.76-$0.70-$1.11 - -$0.63-8.57%MissN/A72 up, 0 downOct 27, 2022$28.07M
    Jun 30, 2022-$0.65-$0.70-$1.01 - -$0.51+7.14%BeatN/A80 up, 1 downAug 4, 2022$54.17M
    Mar 31, 2022-$0.82-$0.73-$1.03 - -$0.63-12.33%MissN/A70 up, 1 downMay 5, 2022$48.49M
    Dec 31, 2021-$0.61-$0.50-$1.14 - -$0.33-22.00%MissN/A61 up, 0 downFeb 24, 2022$57.25M
    Sep 30, 2021-$0.13-$0.48N/A+72.92%BeatN/A41 up, 0 downOct 28, 2021$68.22M
    Jun 30, 2021-$0.39-$0.50N/A+22.00%BeatN/A6N/AJul 29, 2021$54.62M
    Mar 31, 2021-$0.55-$0.30-$0.68 - -$0.22-83.33%MissN/A7N/AMay 6, 2021$47.41M
    Dec 31, 2020-$0.48-$0.47-$0.71 - -$0.28-2.13%MissN/A8N/AMar 1, 2021$50.98M
    Sep 30, 2020-$0.11-$0.29N/A+62.07%BeatN/AN/AN/ANov 5, 2020$51.14M
    Jun 30, 2020-$0.22-$0.36N/A+38.89%BeatN/AN/AN/AJul 30, 2020$48.43M
    Mar 31, 2020-$0.20-$0.52N/A+61.54%BeatN/AN/AN/AMay 11, 2020$47.77M
    Dec 31, 2019-$0.26-$0.37N/A+29.73%BeatN/AN/AN/AFeb 24, 2020$46.69M
    Sep 30, 2019-$0.66-$0.60N/A-10.00%MissN/AN/AN/AOct 30, 2019$44.37M
    Jun 30, 2019-$0.58-$0.40N/A-45.00%MissN/AN/AN/AAug 6, 2019$44.71M
    Mar 31, 2019-$0.63-$0.36N/A-75.00%MissN/AN/AN/AMay 7, 2019$39.57M
    Dec 31, 2018-$0.18-$0.48N/A+62.50%BeatN/AN/AN/AFeb 26, 2019$43.77M
    Sep 30, 2018-$0.68-$0.26N/A-161.54%Miss-553.3%N/AN/ANov 1, 2018$40.71M
    Jun 30, 2018-$0.25-$0.11N/A-127.27%Miss-933.3%N/AN/AJul 26, 2018$41.34M
    Mar 31, 2018-$0.14-$0.36N/A+61.11%Beat-1500.0%N/AN/AMay 1, 2018$38.43M
    Dec 31, 2017-$0.45-$0.19N/A-136.84%MissN/AN/AN/AFeb 27, 2018$42.18M
    Sep 30, 2017$0.15-$0.04N/A+475.00%BeatN/AN/AN/ANov 7, 2017$40.34M
    Jun 30, 2017$0.03$0.03N/A0.00%In line-57.1%N/AN/AAug 9, 2017$38.80M
    Mar 31, 2017$0.01-$0.26N/A+103.85%Beat-92.9%N/AN/AMay 4, 2017$33.62M
    Dec 31, 2016-$0.23-$0.26N/A+11.54%BeatN/AN/AN/AMar 1, 2017$37.33M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.90, a profit after a loss of $3.09 per share the year before. It was -$0.11 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.90N/A
    Dec 31, 2024-$3.09N/A
    Dec 31, 2023-$0.26N/A
    Dec 31, 2022-$3.26N/A
    Dec 31, 2021-$1.68N/A
    Dec 31, 2020-$1.01N/A
    Dec 31, 2019-$2.13N/A
    Dec 31, 2018-$1.25N/A
    Dec 31, 2017-$0.26N/A
    Dec 31, 2016-$0.11N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,36718
    2026Q2Jun 30, 20266,94219
    2026Q1Mar 31, 20266,82919
    2025Q4Dec 31, 20257,46219
    2025Q3Sep 30, 20256,66719
    2025Q2Jun 30, 20256,45619
    2025Q1Mar 31, 20257,17517
    2024Q4Dec 31, 20248,65819

    2026Q3 Earnings Call

    Opening remarks

    Nivi Nehra Investor Relations Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' Third Quarter 2026 Financial Results and Corporate Update Call. Thank you all for joining. Today's call will be led by Dr. Eric Dube, our president and chief executive officer. Eric will be joined in the prepared remarks by Peter Heerma, our chief commercial officer; Dr. Jula Inrig, our head of R&D and chief medical officer; and Christopher Cline, our chief financial officer. William E. Rote, our chief research officer, will join us for the Q&A. Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statements. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, November 2, 2026. Travere specifically disclaims any obligation to update such statements to reflect future information, events, or circumstances. With that, let me now turn the call over to Eric.

    Eric Dube President and Chief Executive Officer Good afternoon. Thank you for joining us today as we discuss another quarter of excellent execution and continued momentum across Travere's commercial business and pipeline. Before turning to our results, I would like to briefly reflect on my upcoming transition that was announced during the quarter. As I prepare to step down in December, I have been reflecting on the people and purpose that have shaped my time at Travere. Being part of this company has been the greatest privilege of my career, and I am deeply proud of what we have accomplished. I have never been more confident that Travere's best days are ahead, with an exceptional executive team, life-changing therapies, a growing pipeline, and an organization committed to delivering for patients. I have been in regular communication with Bradley as we plan for him joining Travere on December 1. This time together has only strengthened my conviction that he is the perfect fit to lead Travere into its next chapter. He shares our commitment to patients and brings the experience, perspective, and leadership to build on our momentum. We are approaching this transition from a position of strength, and you will hear that reflected in the progress we are sharing today.

    Frequently Asked Questions About TVTX

    Did TVTX beat earnings estimates last quarter?

    No. Travere Therapeutics reported EPS of -$0.55 for the quarter ended Sep 30, 2026, below the -$0.25 estimate by 120.00%.

    What EPS do analysts expect from TVTX next quarter?

    The consensus EPS estimate for Travere Therapeutics for the quarter ending Dec 31, 2026 is $0.48 from 16 analysts, with estimates from $0.09 to $0.99.

    How often does TVTX beat earnings estimates?

    Travere Therapeutics beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +125.44%.